ClinicalTrials.gg
RecruitingNCT06776549J-NEUROUpdated Aug 7, 2026

Hypothermia Versus Normothermia After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest

An interventional study of Temperature control and Temperature control in Out-of-hospital Cardiac Arrest (OHCA), ECMO Treatment and Temperature, sponsored by Kagawa University. Recruiting at 29 sites in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Kagawa University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
468
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The SAVE-J NEUROTHERM trial is a cluster randomized trial that evaluated and compared the mortality risk, neurological outcomes, and adverse events between patients who underwent hypothermia and those who underwent normothermia after extracorporeal cardiopulmonary resuscitation for out-of-hospital cardiac arrest.

Read the detailed description

Temperature control is a key neurointensive care for post-cardiac arrest patients. Although therapeutic hypothermia has been shown to be effective in the past, recent large randomized controlled trials have failed to demonstrate its efficacy. The international guidelines recommend temperature control under 37.7°C. However, the optimal temperature control, i.e., hypothermia versus normothermia, remains controversial. Additionally, randomized controlled trials that examined temperature control after extracorporeal cardiopulmonary resuscitation (ECPR) are lacking.

ECPR is a resuscitation technique using extracorporeal membrane oxygenation (ECMO) for refractory cardiac arrest. In ECPR patients, ECMO using a heat exchanger can more rapidly achieve the targeted temperature as compared to other temperature control devices. Early cooling to achieve hypothermia after resuscitation is expected to be more effective for neuroprotection in the injured brain. Thus, the investigators hypothesized that hypothermia would be effective in ECPR patients.

Furthermore, ECMO can stabilize the respiratory and circulatory status. Therefore, hypothermia, which may have side effects such as electrolyte abnormalities and arrhythmias, may be safely performed by ECMO. However, ECMO requires the administration of anticoagulants; therefore, it has the risk of hemorrhagic complications. Among patients receiving ECPR, bleeding is a common complication due to its relatively difficult procedure, considering the fact that emergent cannulation is performed under resuscitation. Additionally, CPR-related complications can also result in bleeding. These complications may be enhanced by hypothermia. Therefore, hypothermia after ECPR could contribute to a favorable outcome, but it could also cause bleeding.

The SAVE-J NEUROTHERM trial is a cluster randomized trial that evaluated and compared the mortality risk, neurological outcomes, and adverse events between out-of-hospital cardiac arrest (OHCA) patients who underwent hypothermia and normothermia after ECPR.

02

Conditions studied

  • Out-of-hospital Cardiac Arrest (OHCA)
  • ECMO Treatment
  • Temperature
  • Post Cardiac Arrest Syndrome

Keywords

  • Cardiac arrest
  • Out-of-hospital cardiac arrest (OHCA)
  • Extracorporeal cardiopulmonary resuscitation (ECPR)
  • Temperature control
  • Post cardiac arrest syndrome (PCAS)
03

In context

Out-of-Hospital Cardiac Arrest

314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.

This study's planned enrollment of 468 is above the median of 218 across 179 interventional studies indexed under Out-of-Hospital Cardiac Arrest.

Browse Out-of-Hospital Cardiac Arrest studies →

Lead sponsor

Kagawa University is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • OHCA
  • Age of 18-75 years, known or estimated
  • An initial cardiac arrest rhythm of ventricular fibrillation/pulseless ventricular tachycardia or pulseless electrical activity

Exclusion criteria

Exclusion Criteria:

  • ECMO initiated after sustained return of spontaneous circulation (ROSC) and patients with sustained ROSC before ECMO initiation
  • OHCA of presumed non-cardiac etiology
  • Time from emergency call or witnessed arrest to hospital arrival of >60 min
  • Time from hospital arrival to ECMO initiation of >60 min
  • Pre-hospital ECPR
  • Unavailability of the ECMO heat exchanger for temperature control
  • Glasgow Coma Scale score before temperature control of >8
  • Core body temperature upon hospital arrival of ≤32ºC
  • Surgical intervention before temperature control (e.g., surgical intervention for the primary disease or complications related to resuscitation/ECMO procedures)
  • Do Not Attempt Resuscitation) order confirmed prior to temperature control
  • Limitations in intensive care before temperature control
  • Known cerebral performance category (CPC) of 3-4 before cardiac arrest
  • Known with home oxygen therapy
  • Known or suspected pregnancy
  • Concomitant illness, such as , shortens (180-day survival unlikely)
  • Consent not obtained or withdrawn by the participant or surrogate
  • Other reasons, physician's decision not to enroll the patient
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
468 participants (estimated)

Study arms

  • Active comparator
    Normothermia

    Temperature control at 36 °C

    Procedure: Temperature control

  • Experimental
    Hypothermia

    Temperature control at 33-34 °C

    Procedure: Temperature control

Interventions

  • ProcedureTemperature control

    Procedure: Temperature control at 33-34 °C In the hypothermia group, patients receiving ECPR will be immediately cooled to 33ºC-34ºC with ECMO using a heat exchanger. After reaching this targeted temperature, the maintenance phase will start, and the target temperature will be kept at 33ºC-34°C. The maintenance phase will end 24 h after reaching this targeted temperature. Subsequently, rewarming to 36ºC-37ºC will be conducted in 24 h. After the rewarming, the temperature will be kept in the range of 36ºC-37.5ºC for 24 h after rewarming or until the end of ECMO, and should not exceed 37.5ºC. Other interventions, such as sedation, administration of neuromuscular blocking agents, antipyretics, and catecholamines, as well as mechanical circulatory support, are optional and performed at the patient's discretion.

  • ProcedureTemperature control

    Procedure: Temperature control at 36 °C In the normothermia group receiving ECPR, the temperature of 36ºC will be immediately reached with ECMO using a heat exchanger. After reaching this targeted temperature, the maintenance phase will start, and the target temperature will be maintained at 36ºC. The maintenance phase will end 24 h after reaching this targeted temperature. Then, rewarming to 36ºC-37ºC will be conducted in 24 h. After the rewarming, the temperature will be kept in the range of 36ºC-37.5ºC for 24 h after rewarming or until the end of ECMO, and should not exceed 37.5ºC. Other interventions, such as sedation, administration of neuromuscular blocking agents, antipyretics, and catecholamines, as well as mechanical circulatory support, are optional and performed at the patient's discretion.

06

What researchers measure

Primary outcomes

  1. Survival

    Time frame: At discharge (approximately 25 days)

Secondary outcomes

  1. Survival

    Time frame: At 30 days, 90 days, and 1 year after admission

  2. Neurological function: Cerebral performance categories (CPC)

    The range of cerebral performance category (CPC) score is from 1 (normal/good cerebral function) to 5 (brain death or death). The higher the score, the worse the outcome. A favorable neurological outcome was defined as a CPC of 1-2, whereas an unfavorable outcome was defined as a CPC of 3-5

    Time frame: At discharge (approximately 25 days), 30 days, 90 days, and 1 year after admission

  3. Adverse events

    Adverse events during intensive care unit stay (arrhythmia, bleeding, pneumonia, and bacteremia)

    Time frame: During the intensive care unit stay, an average of 2 weeks

07

Study locations

27 of 29 sites recruiting
  • Kurume University Hospital
    Kurume, Fukuoka 8300011, Japan
    Recruiting
    • Maki Otsuka · Principal investigator
  • Asahikawa Medical University Hospital
    Asahikawa, Hokkaido 0788510, Japan
    Not yet recruiting
    • Akihito Tampo · Principal investigator
  • Sapporo Medical University Hospital
    Sapporo, Hokkaido 0608556, Japan
    Recruiting
    • Ryuichiro Kakizaki · Principal investigator
  • Hokkaido University Hospital
    Sapporo, Hokkaido 0608648, Japan
    Recruiting
    • Takeshi Wada · Principal investigator
  • Hyogo Prefectural Kakogawa Medical Center
    Kakogawa, Hyōgo 6758555, Japan
    Recruiting
    • Atushi Tanaka · Principal investigator
  • Hyogo Emergency Medical Center
    Kobe, Hyōgo 6510073, Japan
    Recruiting
    • Shinichi Ijuin · Principal investigator
    • Takeshi Nishimura · Sub investigator
  • Toyooka Public Hospital
    Toyooka, Hyōgo 6688501, Japan
    Recruiting
    • Futoshi Nagashima · Principal investigator
  • Hitachi General Hospital
    Hitachi-shi, Ibaraki 317-0077, Japan
    Recruiting
    • Yuji Takahashi · Principal investigator
  • Kagawa University Hospital
    Kita-gun, Kagawa-ken 7610793, Japan
    Recruiting
    • Kenya Kawakita · Principal investigator
    • Takuya Taira · Sub investigator
  • Oshima Prefectural Hospital
    Amami, Kagoshima-ken 8940015, Japan
    Recruiting
    • Kentaro Nakamura · Principal investigator
  • Ebina General Hospital
    Ebina, Kanagawa 2430432, Japan
    Recruiting
    • Takahiro Yukawa · Principal investigator
  • Saiseikai Yokohamashi Tobu Hospital
    Yokohama, Kanagawa 2308765, Japan
    Recruiting
    • Kosei Omasa · Principal investigator
  • Kyoto Second Red Cross Hospital
    Kyoto, Kyoto 6028026, Japan
    Not yet recruiting
    • Kenji Kandori · Principal investigator
  • Tohoku University Hospital
    Sendai, Miyagi 9808574, Japan
    Recruiting
    • Shigeki Kushimoto · Principal investigator
  • Sendai Medical Center
    Sendai, Miyagi 9838520, Japan
    Recruiting
    • Yu Kawazoe · Principal investigator
  • Okayama University Hospital
    Okayama, Okayama-ken 7008558, Japan
    Recruiting
    • Tetsuya Yumoto · Principal investigator
  • Tsuyama Chuo Hospital
    Tsuyama, Okayama-ken 7080841, Japan
    Recruiting
    • Hiroki Maeyama · Principal investigator
  • Okinawa Prefectural Nanbu Medical Center & Children's Medical Center
    Shimajiri-gun, Okinawa 9011193, Japan
    Recruiting
    • Kota Hoshino · Principal investigator
  • Osaka Saiseikai Senri Hospital
    Suita, Osaka 5650862, Japan
    Recruiting
    • Hirotaka Sawano · Principal investigator
  • Saitama Red Cross Hospital
    Saitama, Saitama 3308553, Japan
    Recruiting
    • Syunichi Kato · Principal investigator
  • Tottori Prefectural Central Hospital
    Tottori-shi, Tottori 6800901, Japan
    Recruiting
    • Makoto Kobayashi · Principal investigator
  • St. Luke's International Hospital
    Tokyo, 1048560, Japan
    Recruiting
    • Shutaro Isokawa · Principal investigator
    • Kasumi Shirasaki · Sub investigator
  • Institute of Science Tokyo Hospital
    Tokyo, 1138519, Japan
    Recruiting
    • Wataru Takayama · Principal investigator
  • Nippon Medical School Hospital
    Tokyo, 1138603, Japan
    Recruiting
    • Toru Takiguchi · Principal investigator
    • Takuro Hamaguchi · Sub investigator
  • Tokyo Metropolitan Bokutoh Hospital
    Tokyo, 1308575, Japan
    Recruiting
    • Kazuhiro Sugiyama · Principal investigator
    • Taichi Kato · Sub investigator
  • Keio University Hospital
    Tokyo, 1608582, Japan
    Recruiting
    • Ryo Yamamoto · Principal investigator
  • Japanese Red Cross Musashino Hospital
    Tokyo, 1808610, Japan
    Recruiting
    • Manato Watanabe · Principal investigator
  • Tokyo Metropolitan Tama Medical Center
    Tokyo, 1838524, Japan
    Recruiting
    • Yuichi Horikoshi · Principal investigator
  • National Hospital Organization Disaster Medical Center
    Tokyo, 1900014, Japan
    Recruiting
    • Kazushige Inoue · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2029, 48 months after the start.

Of 93 non-industry interventional studies with no phase under Out-of-Hospital Cardiac Arrest, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 48 months is above that.

Counting every sponsor, half of 95 studies reached it within 34 months; a quarter within 19 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2025
First posted
Jan 15, 2025
StartActual
Jan 6, 2025
Primary completionEst.
Jan 31, 2029
CompletionEst.
Jan 31, 2030
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06776549
Lead sponsor
Kagawa University
Responsible party
Akihiko Inoue (Principal Investigator, Kagawa University) — Principal investigator
First posted
Jan 15, 2025
Start date
Jan 6, 2025
Primary completion
Jan 31, 2029 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Aug 7, 2026

Study contacts

Akihiko Inoue
Contact
j-neuro@googlegroups.com
81-87-981-2392
Akihiko Inoue
principal investigator · Hyogo Emergency Medical Center
Yasuhiro Kuroda
study chair · Kagawa University
Toru Hifumi
study chair · Kyorin University School of Medicine
Tetsuya Sakamoto
study director · Teikyo University
Naoaki Ichihara
study director · Osaka University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion